Dr. Benjamin Hippen speaks about the Iranian system that allows an individual's kidney to be sold by the donor, whom we can also think of as the vendor. Examination has shown that the recipients are on a level playing field and there is no tourism or fraud. The responsibility for recruiting potential vendors becomes separated from the responsibility for approving the vendor's medical and surgical candidacy. But moral concerns in the US may have to be resolved in the future by a hybrid system that combines features of both systems.
Can Commoditization and Altruism of Organ Transplantation Coexist?
Restart
Resume
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Recommended
Details
Presenters
Overview
Dr. Benjamin Hippen speaks about the Iranian system that allows an individual's kidney to be sold by the donor, whom we can also think of as the vendor. Examination has shown that the recipients are on a level playing field and there is no tourism or fraud. The responsibility for recruiting potential vendors becomes separated from the responsibility for approving the vendor's medical and surgical candidacy. But moral concerns in the US may have to be resolved in the future by a hybrid system that combines features of both systems.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Cardiology
Phase 3 study results of plozasiran in patients with FCS
<p>Phase 3 study results of plozasiran in patients with FCS</p>
CME/CE
FCS and SHTG: Are We Meeting the Need?
0.25 credits
<p>FCS and SHTG: Are We Meeting the Need?</p>
CME/CE
Evolutions in Duchenne Muscular Dystrophy: Treatment Implications for the Present and Future
1.00 credits
<p>Evolutions in Duchenne Muscular Dystrophy: Treatment Implications for the Present and Future</p>
CME/CE
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective
0.25 credits
<p>Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective</p>
MinuteCE®
Integrating Guideline Directed Medical Therapy for Patients with CKD and T2D
1.00 credits
<p>Integrating Guideline Directed Medical Therapy for Patients with CKD and T2D</p>
Cardiology
Effect of Finerenone on NT-proBNP in HFmrEF/HFpEF: FINEARTS-HF Trial
<p>Effect of Finerenone on NT-proBNP in HFmrEF/HFpEF: FINEARTS-HF Trial </p>
Cardiology
Kidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial
<p>Kidney Risk Stratification in Finerenone Treatment: FINEARTS-HF Trial</p>
Cardiology
Mode of Death in Patients With HFmrEF/HFpEF: The FINEARTS-HF Trial
<p><span data-teams="true">Mode of Death in Patients With HFmrEF/HFpEF: The FINEARTS-HF Trial</span> </p>
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?